Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

• Published in: Nature medicine Vol. 13; no. 11; pp. 1359 - 1362
• Main Authors: Ray, Sandip, Britschgi, Markus, Herbert, Charles, Takeda-Uchimura, Yoshiko, Boxer, Adam, Blennow, Kaj, Friedman, Leah F, Galasko, Douglas R, Jutel, Marek, Karydas, Anna, Kaye, Jeffrey A, Leszek, Jerzy, Miller, Bruce L, Minthon, Lennart, Quinn, Joseph F, Rabinovici, Gil D, Robinson, William H, Sabbagh, Marwan N, So, Yuen T, Sparks, D Larry, Tabaton, Massimo, Tinklenberg, Jared, Yesavage, Jerome A, Tibshirani, Robert, Wyss-Coray, Tony
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.11.2007; Nature Publishing Group
• Subjects: Alzheimer Disease - blood; Alzheimer Disease - classification; Alzheimer Disease - diagnosis; Alzheimer's disease; Biological analysis; Biomarkers - blood; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell and Molecular Biology; Cell- och molekylärbiologi; Cellular biology; Classification; Clinical Medicine; Cognition Disorders - blood; Cognition Disorders - classification; Cognition Disorders - diagnosis; Cognitive ability; disease; gene-expression; Humans; immune; Infectious Diseases; Intercellular Signaling Peptides and Proteins - blood; Klinisk medicin; letter; Medical and Health Sciences; Medical diagnosis; Medicin och hälsovetenskap; Metabolic Diseases; mild cognitive impairment; Molecular Biology; Molecular Medicine; Molekylärbiologi; Neurologi; Neurology; Neurosciences; Phenotype; Plasma; Predictive Value of Tests; Proteins; responses; Signal transduction
• ISSN: 1078-8956; 1546-170X; 1546-170X
• DOI: 10.1038/nm1653

A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2–6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.